CN105777609A - 一种7-苯甲酰基-1,3-二氢吲哚-2-酮的制备方法 - Google Patents
一种7-苯甲酰基-1,3-二氢吲哚-2-酮的制备方法 Download PDFInfo
- Publication number
- CN105777609A CN105777609A CN201610229006.5A CN201610229006A CN105777609A CN 105777609 A CN105777609 A CN 105777609A CN 201610229006 A CN201610229006 A CN 201610229006A CN 105777609 A CN105777609 A CN 105777609A
- Authority
- CN
- China
- Prior art keywords
- benzoyl
- preparation
- indoline
- ketone
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000006243 chemical reaction Methods 0.000 claims abstract description 31
- 239000003054 catalyst Substances 0.000 claims abstract description 9
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 5
- 239000004327 boric acid Substances 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229960001002 nepafenac Drugs 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 17
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 15
- 150000002576 ketones Chemical class 0.000 description 15
- 239000003814 drug Substances 0.000 description 10
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 6
- 229940127108 compound 5g Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000012535 impurity Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- -1 7 cyanoindole ketone Chemical class 0.000 description 1
- IPHMDNXLZVKWES-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)C1=CC=CC=C1.[Br] Chemical compound C(C1=CC=CC=C1)(=O)C1=CC=CC=C1.[Br] IPHMDNXLZVKWES-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
Abstract
本发明公开了一种7‑苯甲酰基‑1,3‑二氢吲哚‑2‑酮的制备方法,其具体步骤:在反应器加入2‑氨基‑3‑苯甲酰基苯乙酰胺,加入有机溶剂至溶清为止,加入催化剂,控温反应,反应完后,减压浓缩得到7‑苯甲酰基‑1,3‑二氢吲哚‑2‑酮。本发明的方法工艺稳定,操作简单,收率高,纯度高,无需苛刻的反应条件,所需温度压力均在常规范围内,所用试剂无毒,污染小,是一种经济的制备7‑苯甲酰基‑1,3‑二氢吲哚‑2‑酮的方法。
Description
技术领域:
本发明属有机化学领域,为环合反应,尤其涉及一种7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的制备方法。
背景技术:
奈帕芬胺是由美国Alcon公司研发,2005年8月FDA批准用于治疗与白内障手术相关的疼痛和炎症的一种新型眼用非甾体类解热镇痛抗炎药,具有渗透力强、靶向作用强,毒副作用小等优点。
新药研究和开发过程中,药物的质量是衡量药物品质的一个重要标准,药物的质量很大程度上取决于药物的有效成分含量。药物的有效成分的含量是反应药物纯度的重要标志,而药物中存在的杂质直接影响到药物的疗效并可能导致毒副作用的产生。药物的杂质式生产、储运过程中的引进或产生药物以外的其他化学物质,杂质的存在不仅影响药物的纯度,还会带来非治疗活性的毒副作用,必须加以控制。
在奈帕芬胺稳定性放置过程中会产生杂质,其结构式如式Ⅰ所示。
式Ⅰ化合物的合成方法见于Chenjiuxi发表在Org.Biomol.Chem上的文章,其主要合成思路概括如下:
该方法以7‐氰基吲哚酮为原料与苯硼酸发生反应生成式Ⅰ化合物。
从上述方法中可以看出该反应用到危险的钯催化剂,溶剂为有毒溶剂2‐甲基四氢呋喃,都是非常见的化工原料。且反应温度较高,反应时间较长,综上反应比较苛刻。
式Ⅰ化合物的合成方法见于Young S.Lo等人发表于J.HeterocyclicChem, 17,1663(1980)的Synthesis of 2‐Amino‐3‐benzoylphenylacetic Acid中,其主要合成思路概括如下:
该方法以吲哚林为原料与苯腈为原料经过付克酰基化得到化合物3,化合物3经过二氧化锰氧化得到化合物4后经过氯带得到化合物5,化合物5在硼酸的作用下得到式Ⅰ化合物。
从上述方法中我们可以看出第一步需经过付克酰基化反应,该反应收率低,且三氯化铝有毒对环境危害大。总反应步骤繁琐总收率低。
化合物Ⅰ的合成方法见于David A.Walsh等人发表在JMC的
2‐Amino‐3‐benzoylphenylacet ic Acid and Analogues中,其主要思路可以概括为:
该路线以2‐硝基3‐溴二苯甲酮为原料,经取代生成化合物7,化合物7经过锌粉还原得到式Ⅰ化合物。
该路线用到丙二酸二乙酯,需要碱性较高的缚酸剂引发反应,条件要求较高。锌粉为易制爆化学品,危险性较高。所以该路线繁琐,且收率较低。
发明内容:
本发明针对现有的技术不足而提供一种成本低,收率高,可控性强,纯度高的7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮制备方法。
本发明的技术方案为:一种7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的制备方法,其合成路线如下:
其具体步骤为:
在反应器加入2‐氨基‐3‐苯甲酰基苯乙酰胺,加入有机溶剂至溶清为止,加入催化剂,控温反应,反应完后,减压浓缩得到7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮。
优选上述的催化剂为盐酸、硫酸、硝酸、碳酸或硼酸。优选上述催化剂的质量浓度为10%~50%。更优选质量浓度为30%~50%。
优选上述的有机溶剂为乙酸乙酯、四氢呋喃、乙醇、甲醇、正丙醇、N,N‐二甲基甲酰胺或环己烷。
优选控温反应的温度为10℃~90℃;更优选为20℃~30℃。反应时间为2h~8h,反应时间随温度提高而减少。
优选所述化合物2‐氨基‐3‐苯甲酰基苯乙酰胺与催化剂的摩尔比为1:(1~3),更优选为1:(1~2)。
有益效果:
本发明的方法工艺稳定,操作简单,收率高,纯度高,无需苛刻的反应条件,所需温度压力均在常规范围内,所用试剂无毒,污染小,是一种经济的制备7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的方法。
附图说明:
图1为实施例1所制备的7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的液相图;
图2为实施例1所制备的7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的氢谱图。
具体实施方式:
实施例1:7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的制备
式a所示化合物5g(19.66mmol),加入250ml反应瓶中,加入乙醇100ml,搅拌溶解,滴加3.86g质量分数为37%盐酸(39.33mmol)溶液,30℃反应3h,TLC监测反应结束,减压浓缩得白色固体4.33g,收率92.1%。纯度99.97%。从图1可以得出7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的纯度如下表所示:
峰表
峰 | 保留时间 | 面积 | 高度 | 面积 | 高度 |
1 | 3.733 | 1539 | 148 | 0.005 | 0.006 |
2 | 7.175 | 32798175 | 2538735 | 99.971 | 99.977 |
3 | 9.867 | 2352 | 157 | 0.007 | 0.006 |
4 | 11.144 | 3399 | 149 | 0.010 | 0.006 |
5 | 14.916 | 1327 | 68 | 0.004 | 0.003 |
6 | 16.959 | 797 | 67 | 0.002 | 0.003 |
总计 | 32807589 | 2539324 | 100.00 | 100.00 |
所制得的7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的氢谱图如图2所示:
1H NMR(400MHz,DMSO)δ10.33(s,1H),7.71(t,J=7.1Hz,2H),7.67(t,J=7.1Hz,1H),7.56(t,J=7.4Hz,2H),7.47(d,J=7.1Hz,1H),7.32(t,J=8.3Hz,1H),7.04(t,J=7.6Hz,1H)。
实施例2:7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的制备
式a所示化合物5g(19.66mmol),加入250ml反应瓶中,加入乙酸乙酯100ml,搅拌溶解,滴加5.30g的质量分数为40%硫酸(21.63mmol)溶液,20℃反应5h,TLC监测反应结束,减压浓缩得白色固体4.05g,收率86.1%。纯度98.3%
实施例3:7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的制备
式a所示化合物5g(19.66mmol),加入250ml反应瓶中,加入乙醇100ml,搅拌溶解,滴加6.42g质量分数为45%硼酸(29.49mmol)溶液,80℃反应4h,TLC 监测反应结束,减压浓缩得白色固体3.75g,收率79.6%。纯度97.6%
实施例4:7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的制备
式a所示化合物5g(19.66mmol),加入250ml反应瓶中,加入乙醇100ml,搅拌溶解,滴加6.42g质量分数为45%硼酸(29.49mmol)溶液,25℃反应7h,TLC监测反应结束,减压浓缩得白色固体3.65g,收率77.6%。纯度98.7%
实施例5:7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的制备
式a所示化合物5g(19.66mmol),加入250ml反应瓶中,加入四氢呋喃100ml,搅拌溶解,滴加7.13g质量分数为30%硝酸(33.43mmol)溶液,50℃反应6h,TLC监测反应结束,减压浓缩得白色固体3.79g,收率80.6%。纯度97.1%
实施例6:7‐苯甲酰基‐1,3‐二氢吲哚‐2‐酮的制备
式a所示化合物5g(19.66mmol),加入250ml反应瓶中,加入N,N‐二甲基甲酰胺100ml,搅拌溶解,滴加3.86g质量分数为37%盐酸(39.33mmol)溶液,30℃反应3h,TLC监测反应结束,减压浓缩得白色固体4.16g,收率88.5%。纯度96.9%。
Claims (6)
1.一种7-苯甲酰基-1,3-二氢吲哚-2-酮的制备方法,其具体步骤:
在反应器加入2-氨基-3-苯甲酰基苯乙酰胺,加入有机溶剂至溶清为止,加入催化剂,控温反应,反应完后,减压浓缩得到7-苯甲酰基-1,3-二氢吲哚-2-酮。
2.根据权利要求1所述的制备方法,其特征在于所述的催化剂为盐酸、硫酸、硝酸、碳酸或硼酸。
3.根据权利要求2所述的制备方法,其特征在于所述催化剂的质量浓度为10%~50%。
4.根据权利要求1所述的制备方法,其特征在于所述的有机溶剂为乙酸乙酯、四氢呋喃、乙醇、甲醇、正丙醇、N,N-二甲基甲酰胺或环己烷。
5.根据权利要求1所述的制备方法,其特征在于控温反应的温度为10℃~90℃;反应时间为2h~8h。
6.根据权利要求1所述的制备方法,其特征在于所述化合物2-氨基-3-苯甲酰基苯乙酰胺与催化剂的摩尔比为1:(1~3)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610229006.5A CN105777609A (zh) | 2016-04-13 | 2016-04-13 | 一种7-苯甲酰基-1,3-二氢吲哚-2-酮的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610229006.5A CN105777609A (zh) | 2016-04-13 | 2016-04-13 | 一种7-苯甲酰基-1,3-二氢吲哚-2-酮的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105777609A true CN105777609A (zh) | 2016-07-20 |
Family
ID=56397386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610229006.5A Pending CN105777609A (zh) | 2016-04-13 | 2016-04-13 | 一种7-苯甲酰基-1,3-二氢吲哚-2-酮的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105777609A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1962656A (zh) * | 2006-11-29 | 2007-05-16 | 沈阳药科大学 | 吲哚美辛5-氟尿嘧啶甲酯药用化合物及其制剂和制备方法 |
-
2016
- 2016-04-13 CN CN201610229006.5A patent/CN105777609A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1962656A (zh) * | 2006-11-29 | 2007-05-16 | 沈阳药科大学 | 吲哚美辛5-氟尿嘧啶甲酯药用化合物及其制剂和制备方法 |
Non-Patent Citations (2)
Title |
---|
JAGADEESH BABU NANUBOLU,等: "Conformational and crystal energetics of a polymorphic cyclized product of Napafenac: The Z0 and crystal stability correlation", 《JOURNAL OF MOLECULAR STRUCTURE》 * |
MISLAV RUNJE,等: "Forced degradation of nepafenac: Development and validation of ofstability indicating UHPLC method", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101798270B (zh) | 一种3-氨基-1-金刚烷醇的制备方法 | |
CN107445909B (zh) | 一种丙硫菌唑中间体的制备方法 | |
CN103601686A (zh) | 一锅法合成含氟的嘧啶类化合物的方法 | |
CN101633643B (zh) | 一种奥硝唑的合成方法 | |
CN103420902A (zh) | 一种2-氯-4-碘-5-甲基吡啶的制备方法 | |
CN105777609A (zh) | 一种7-苯甲酰基-1,3-二氢吲哚-2-酮的制备方法 | |
CN104341360A (zh) | 一种卢非酰胺的制备方法 | |
CN111116551B (zh) | 1-氮杂螺[5.5]十一烷-3-酮类及1-氮杂螺[5.5]十一烷-3-醇类化合物 | |
CN110804022B (zh) | 一种右丙亚胺的制备方法 | |
CN103319417A (zh) | 三氯苯达唑亚砜的制备方法 | |
CN104151170A (zh) | 4-硝基苯乙胺盐酸盐及其制备方法 | |
CN102731408A (zh) | 一种阿齐沙坦中间体及其制备方法 | |
CN103664941B (zh) | 一种长春西汀类似物的制备方法 | |
CN114181117A (zh) | 一种帕拉米韦中间体的制备方法 | |
CN104003887A (zh) | 一种盐酸溴己新的制备方法 | |
CN109503355A (zh) | 一种对氯甲基苯甲酸的制备方法 | |
CN104926660B (zh) | 一种三硝基间苯三酚的绿色合成方法及应用 | |
CN110305083B (zh) | 一种以果糖制备5-氯甲基糠醛的工艺 | |
CN101863836A (zh) | 制备5,5-二苯基-2-硫代海因的方法 | |
CN102875499A (zh) | 3-氨甲基氧杂环丁烷及其有机酸盐的制备方法 | |
CN101538201B (zh) | 阿戈美拉汀中间体(7-甲氧基-1-萘基)乙酸酯的制备方法 | |
CN107021928B (zh) | 艾曲波帕新的中间体及其制备方法和应用 | |
CN103183649A (zh) | 2-氨基-6-丙氨基-4,5,6,7-四氢苯并噻唑的制备方法 | |
CN105503839A (zh) | 一种拉帕替尼及其二对甲苯磺酸盐的制备方法 | |
CN103145613A (zh) | 一种(e)-3-(2-环丙基-4-(4-氟苯基))喹啉-2-丙烯醛的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160720 |